{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.5","upperLimit":"90.9","value":"86.6"},{"groupId":"OG001","lowerLimit":"77.4","upperLimit":"88.5","value":"83.8"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.9","upperLimit":"76.7","value":"70.4"},{"groupId":"OG001","lowerLimit":"59.1","upperLimit":"73.2","value":"66.7"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"FAS included all participants who were randomized to study treatment.","reportingStatus":"POSTED","timeFrame":"Month 6, 12","title":"Overall Survival Probability at Months 6 and 12","type":"SECONDARY","unitOfMeasure":"percent chance of survival"}